Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MERUS LABS INTERNATIONAL INC T.MSL

"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."


TSX:MSL - Post by User

Post by melowon Mar 01, 2016 7:26pm
79 Views
Post# 24611060

closed

closed

Merus Labs International Inc. Announces Closing Of $27 Million Bought Deal Financing

Tuesday, March 01, 2016

 

Merus Labs International Inc. Announces Closing Of $27 Million Bought Deal Financing

09:05 EST Tuesday, March 01, 2016


TORONTO, March 1, 2016 /PRNewswire/ - Merus Labs International Inc. ("Merus" or the "Company") (TSX: MSL, NASDAQ: MSLI) is pleased to announce today the closing of its previously announced bought deal financing of subscription receipts (the "Offering") with a syndicate of investment dealers (the "Underwriters").  The Company issued a total of 14,250,000 subscription receipts (the "Subscription Receipts") at a price of $1.90 per Subscription Receipt for gross proceeds of $27,075,000. 


<< Previous
Bullboard Posts
Next >>